Adagene Inc. (ADAG) Stock: Price, Forecast & Analyst Target
Adagene Inc. (ADAG) — MoonshotScore 21/100 (Weak band), calculated Nov 18, 2026. Price $1.76 (-12.44%), as of the Nov 20, 2026 trading session; market cap $118M.
Educational signal · not a buy or sell recommendation · How to read this
Adagene Inc. · ADAG · NASDAQ
Adagene Inc. is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the research and development of monoclonal antibody drugs for various cancers.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Adagene (ADAG)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Durable growth, at a cheap price, but bottom-tier quality and a strained balance sheet. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Strained; Valuation: Cheap; Growth Durability: Growing; Momentum: Slipping.
- quarterly revenue $2M (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 7 of the last 8 reports
- Altman Z -1.92 · Piotroski F 4
Holding back: weak fundamentals, balance-sheet strain, weak price trend
Helping: an attractive price, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 19 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.76 | |
| Change on the day | -12.44% | |
| 52-week range | $1.42 – $4.85 | |
| Market capitalisation | $118M | — |
| Shares traded on the day | 1.37M |
Price & events
Other perspectives
Council score for Adagene (ADAG): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Adagene (ADAG), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Adagene Inc. (ADAG) is listed on NASDAQ. It employs 128 people and is led by Peter Luo. In Q2 FY2026 it reported revenue of $2M and net income of -$16M. The market values it at $118M.
What do the latest results show for Adagene (ADAG)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $2M. Against analyst estimates the company has EPS beat 7 of the last 8 reports.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $2M | -$16M | -$0.36 (diluted) |
| Q4 FY2025 | $8M | -$4M | -$0.11 (diluted) |
| Q4 FY2024 | $103,204 | -$25M | -$0.71 (diluted) |
What are the financial strengths and risks for Adagene (ADAG)?
Short answer · as of
The MoonshotScore pillars rate an attractive price, durable growth as strengths. What is holding it back is weak fundamentals, balance-sheet strain, weak price trend. The distress and quality screens read Altman Z -1.92 · Piotroski F 4. Trailing ratios: ROE -29.1% · ROA -15.4% · current ratio 5.02 · earnings yield -27.8% · free-cash-flow yield -31.7%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -1.92 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-29.1%) — the business is not currently generating profit on shareholder capital.
What should you watch next at Adagene (ADAG)?
Short answer · as of
Current published price targets run low $7.00 · high $10.00 · consensus $8.25 · median $8.00 against a quoted price of $1.76 (as of Nov 20, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Adagene compare with its peers?
Short answer
Adagene's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 18, 2026 | |
| $15.47 Nov 20, 2026 | $86.6M | 82 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 | |
| Adagene (ADAG) — this page | $1.76 | $118M | 21 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $7.00 – $10.00
- Consensus target
- $8.25
- Median target
- $8.00
Consensus record · Captured .
Measured against a quoted price of $1.76 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 23, 2026
- Transactions
- 9
- Identified insiders
- 6
- Purchases
- 5
- Sales
- 0
- Other transactions
- 4
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ADAG in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ADAG in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Adagene (ADAG)?
- Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
- Adagene and City of Hope Launch Phase 1 Clinical Trial for Metastatic Colorectal Cancer Combination Therapy
- City of Hope and Adagene Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer
- Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer
Adagene Stock: Key Questions Answered
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for ADAG?
ADAG carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ADAG a good stock to buy?
Stock Expert AI does not rate ADAG buy, sell or hold. Adagene Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ADAG stock price today?
The last price recorded for Adagene Inc. (ADAG), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ADAG price target?
The analyst consensus price target for Adagene Inc. (ADAG), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key factors to evaluate for ADAG?
Adagene Inc. (ADAG) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Strategic Partnerships and Collaborations: Given its clinical-stage nature and extensive pipeline, Adagene has a significant opportunity to forge strategic partnerships and collaborations with larger pharmaceutical companies. Not financial advice.
How frequently does ADAG data refresh on this page?
ADAG's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ADAG's recent stock price performance?
Adagene Inc. (ADAG) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive and diversified pipeline of monoclonal antibody drug candidates targeting various oncology indications. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ADAG overvalued or undervalued right now?
Adagene Inc. (ADAG) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ADAG before investing?
Before investing in Adagene Inc. (ADAG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 20 figures on this page — 12 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com